Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Change in Accured Expenses (2016 - 2025)

Viking Therapeutics' Change in Accured Expenses history spans 12 years, with the latest figure at $2.1 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 126.37% year-over-year to $2.1 million; the TTM value through Dec 2025 reached $6.2 million, up 6.05%, while the annual FY2025 figure was $6.2 million, 6.05% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was $2.1 million at Viking Therapeutics, up from -$4.8 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $15.9 million in Q1 2024 and bottomed at -$13.6 million in Q2 2024.
  • The 5-year median for Change in Accured Expenses is $250500.0 (2021), against an average of $773550.0.
  • The largest annual shift saw Change in Accured Expenses crashed 862.72% in 2023 before it surged 6472.88% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at -$1.1 million in 2021, then surged by 330.71% to $2.5 million in 2022, then surged by 57.26% to $3.9 million in 2023, then plummeted by 299.8% to -$7.8 million in 2024, then soared by 126.37% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Change in Accured Expenses are $2.1 million (Q4 2025), -$4.8 million (Q3 2025), and $14.6 million (Q2 2025).